Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Bone diseases

Prevention

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Browse the hub

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Visit the hub

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Visit the hub

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.

Visit the conference hub

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

Read the article

Telemedicine in rheumatology

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Browse the hub

Get ready for ACR Convergence 2020

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

Visit the conference hub

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

Osteoporosis therapy: Drug holiday or not?

21-06-2018 | Osteoporosis | Review | Article

Physical activity for fall and fracture prevention

The aim of this review is to provide healthcare professionals with evidence-based physical activity recommendations, and tips for implementing them in practice.

Ponzano M, Rodrigues IB, Giangregorio LM. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0103-5

21-06-2018 | Osteoporosis | Article

Do sarcopenia and/or osteoporosis increase the risk of frailty? A 4-year observation of the second and third ROAD study surveys

Yoshimura N et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4596-4

Physical activity for fall and fracture prevention

The aim of this review is to provide healthcare professionals with evidence-based physical activity recommendations, and tips for implementing them in practice [read more].
Ponzano M, Rodrigues IB, Giangregorio LM. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0103-5



Physical activity for fall and fracture prevention

18-06-2018 | Osteoporosis | Article

Early use of alendronate as a protective factor against the development of glucocorticoid-induced bone loss in childhood-onset rheumatic diseases: A cross-sectional study

Inoue, Y et al. Pediatr Rheumatol 2018; 16: 36. doi: 10.1186/s12969-018-0258-5

04-06-2018 | Osteoporosis | Review | Article

Review of the guideline of the American College of Physicians on the treatment of osteoporosis

Kanis, JA et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4504-y

22-05-2018 | Osteoporosis | Article

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride

Antoniou T et al. BMC Musculoskelet Disord 2018; 19: 160. doi: 10.1186/s12891-018-2076-9

17-05-2018 | Osteoporosis | Article

Anti-osteoporosis drug use: Too little, too much, or just right? The HUNT study, Norway

Hoff M et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4560-3

14-05-2018 | Osteoporosis | Article

Prevalence and comorbidity of osteoporosis: A cross-sectional analysis on 10,660 adults aged 50 years and older in Germany

Puth MT et al. BMC Musculoskelet Disord 2018; 19: 144. doi: 10.1186/s12891-018-2060-4

02-05-2018 | Osteoporosis | Review | Article

Novel imaging modalities in osteoporosis diagnosis and risk stratification

Haque S et al. Curr Treat Options in Rheum 2018; Advance online publication. doi: 10.1007/s40674-018-0099-x

More


More on bone diseases


« Back to main page | Osteoporosis | Clinical trials | Diagnosis and screening | Epidemiology | Fracture | Lifestyle interventions | Medications | Pain | Pathophysiology | Prevention | Quality of life | Risk prediction


Image Credits